Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6815569 | 0.78 | — | — | |
| SCHEMBL8079890 | 0.77 | — | — | |
| SCHEMBL16855884 | 0.77 | LTA4H (0.60) | LTA4H | |
| SCHEMBL12747064 | 0.71 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL100765 | 0.69 | HPGDS (0.46) | HPGDSLTA4H | |
| SCHEMBL16799824 | 0.69 | NOTUM (0.41) | — | |
| SCHEMBL27680672 | 0.69 | HPGDS (0.32) | HPGDSLTA4H | |
| SCHEMBL22638176 | 0.69 | KDM4E (0.43) | HPGDSLTA4H | |
| SCHEMBL21104225 | 0.68 | HPGDS (0.33) | HPGDSLTA4H | |
| SCHEMBL216707 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112521386-A | Polycyclic pyridone compound with antiviral effect and pharmaceutical composition and application thereof | 周雨恬 | 2021-03-19 | — | — | CN | claimed |
| EP-1317444-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-31 | — | — | EP | claimed |
| EP-0931075-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009961-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1998-03-12 | — | — | WO | claimed |
| CN-116157452-A | Composition for forming dielectric film | 富士胶片电子材料美国有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3133068-B1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai hengrui pharmaceutical co ltd (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3133068-A1 | AMIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREFOR AND MEDICINAL APPLICATION THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-8741900-B2 | Phenyl-heteroaryl derivatives and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130079417-A1 | Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-03-28 | — | — | US | disclosed |
| US-8008379-B2 | Fluorescent polymer fine particle, method for forming thereof, fluorescence detection kit, and method for detecting fluorescence | FUJIFILM CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| EP-1903075-B1 | Fluorescent polymer fine particle set, fluorescence detecting complex member set, use of fluorescent polymer fine particle set and fluorescence detecting method | FUJIFILM CORP (JP) | 2010-01-27 | — | — | EP | disclosed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2004014366-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0970080-B1 | IMINO-AZA-ANTHRACYCLINONE DERIVATIVES FOR THE TREATMENT OF AMYLOIDOSIS | PHARMACIA ITALIA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-6262040-B1 | Indazole derivatives and their use as inhibitors of phosphodiesterase (PDE) type IV and the production of tumor necrosis factor (TNF) | PFIZER INC | 2001-07-17 | — | — | US | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0931075-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998009961-A1 | INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE (PDE) TYPE IV AND THE PRODUCTION OF TUMOR NECROSIS FACTOR (TNF) | PFIZER INC. (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079417-A1 | Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor | HTR2C, HTR3B, HTR2B | HPGDS 920/4885LTA4H 1427/4885 |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | HPGDS 277/4885LTA4H 522/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | HPGDS 187/4885LTA4H 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.